Cell/Gene Tx channel feed

#ES­MO22: Adap­ti­m­mune touts new PhI da­ta for its cell ther­a­py treat­ment

3 years ago
R&D

Deer­field backs a Penn spin­out aim­ing to shake up Parkin­son's treat­ments us­ing stem cells, brain surgery

3 years ago
Financing
Startups

Or­ca Bio looks to in­crease its cell ther­a­py man­u­fac­tur­ing ca­pac­i­ty with a new fa­cil­i­ty in Sacra­men­to

3 years ago
Manufacturing

Watch out Mod­er­na: John Maraganore, ARCH and Beam are hatch­ing a plat­form play 'to lead the fu­ture of RNA ther­a­pies'

3 years ago
Startups

On fi­nal dash to the clin­ic, Ar­se­nal­Bio hauls in $220M for 'mod­u­lar' cell ther­a­py ap­proach

3 years ago
Financing

In five pa­tients, Sang­amo’s Fab­ry dis­ease gene ther­a­py ap­pears to be work­ing so far

3 years ago
R&D

Beam re­veals what tripped up its base-edit­ed, off-the-shelf CAR-T as it tries to clear FDA hold

3 years ago
FDA+

Armed with $100M grant, El­e­vate­Bio looks to cre­ate bio­man­u­fac­tur­ing cen­ter with the Uni­ver­si­ty of Pitts­burgh

3 years ago
R&D
Manufacturing

Bio­Marin nets con­di­tion­al ap­proval for val­rox in Eu­rope, mark­ing the first he­mo­phil­ia gene ther­a­py

3 years ago
FDA+

Re­silience part­ners with the Cal­i­for­nia In­sti­tute for Re­gen­er­a­tive Med­i­cine to help cell ther­a­py star­tups

3 years ago
Manufacturing

Sono­ma Bio to ce­ment its roots in Seat­tle with a new wa­ter­front man­u­fac­tur­ing and R&D site

3 years ago
R&D
Manufacturing

With first base edit­ing clin­i­cal tri­al un­der­way, Verve dis­clos­es sec­ond car­dio­vas­cu­lar dis­ease pro­gram

3 years ago
R&D

FDA ap­proves one of the prici­est new treat­ments of all time — blue­bird's gene ther­a­py for be­ta tha­lassemia

3 years ago

Re­silience col­lab­o­rates with the Mayo Clin­ic to man­u­fac­ture rare and com­plex dis­ease drugs

3 years ago
Deals
Manufacturing

CEO of Doud­na spin­out: With­in five years, genome ed­i­tors will have a 're­al­ly big im­pact' on pa­tients' lives

3 years ago

Bris­tol My­ers flash­es a thumbs-up on piv­otal push to ex­pand Abec­ma's BC­MA CAR-T mar­ket

3 years ago
Pharma

Up­dat­ed: 'Close to the mid­dle': Ver­sant launch­es Vec­tor with 'gut­less ade­n­ovirus' de­liv­ery method

3 years ago
Financing
Startups

On an ex­pan­sion spree, Ger­man man­u­fac­tur­er Sar­to­rius makes $500M+ pur­chase of cell cul­ture me­dia play­er

3 years ago
Deals
Outsourcing

Q&A: Astel­las' re­tir­ing head of de­vel­op­ment re­flects on gene ther­a­py deaths

3 years ago
People

UniQure halts high-dose treat­ments of Hunt­ing­ton's drug af­ter 3 pa­tients hos­pi­tal­ized — shares tank

3 years ago
R&D

Al San­drock prunes his post-Bio­gen voy­age with sim­i­lar fo­cus on ALS

3 years ago
R&D

David Hal­lal's El­e­vate­Bio launch­es new com­pa­ny to 'dis­rup­t' off-the-shelf cell ther­a­py, but pro­vides few oth­er de­tails

3 years ago
People
Startups

Two CD­MOs come to­geth­er as they look to ex­pand their reach in cell ther­a­py man­u­fac­tur­ing

3 years ago
Deals
Manufacturing

Gene ther­a­py biotech us­es its man­u­fac­tur­ing sites as col­lat­er­al to net a $100M loan

3 years ago
Financing
Manufacturing
First page Previous page 26272829303132 Next page Last page
A service from the Financial Times